Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.32 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.32 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.31 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.31 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.31 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.31 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.30 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL42417 | 1.00 | KMT2A (0.96) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL2379569 | 1.00 | KMT2A (0.96) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL2379571 | 1.00 | KMT2A (0.96) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL2918479 | 1.00 | KMT2A (0.96) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| SCHEMBL530958 | 0.98 | KMT2A (1.00) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| SCHEMBL13790517 | 0.98 | KMT2A (1.00) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| SCHEMBL13223423 | 0.98 | KMT2A (1.00) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| SCHEMBL47235 | 0.98 | KMT2A (1.00) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| SCHEMBL530957 | 0.98 | KMT2A (1.00) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 | |
| SCHEMBL13790322 | 0.98 | KMT2A (1.00) | KMT2AKDM4ECYP2D6CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527880-B2 | Cyanine-based telodendrimers and uses for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| US-20240299589-A1 | DIAGNOSING AND TREATING CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-09-12 | — | — | US | disclosed |
| US-11813338-B2 | Diagnosing and treating cancer | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210346518-A1 | CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| EP-2850061-B1 | HALOGENATED INDOLE DERIVATIVES FOR PHOTODYNAMIC THERAPY | NANOQUANTUM SCIENCES INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10442930-B2 | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels | VISEN MEDICAL, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20170283617-A1 | Biocompatible N, N-Disubstituted Sulfonamide-Containing Fluorescent Dye Labels | VISEN MEDICAL, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9574085-B2 | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels | VISEN MEDICAL, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9572881-B2 | Halogenated compounds for photodynamic therapy | NANOQUANTUM SCIENCES, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2001042211-A2 | DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1086179-A1 | ENERGY TRANSFER ASSAY METHOD AND REAGENT | Amersham Pharmacia Biotech UK Ltd. (GB) | 2001-03-28 | — | — | EP | disclosed |
| US-6107066-A | Detection of transmembrane potentials by optical methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0977035-A2 | A system for determining the electrical potential across a membrane | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999064519-A1 | ENERGY TRANSFER ASSAY METHOD AND REAGENT | AMERSHAM BIOSCIENCES CORP (GB) | 1999-12-16 | — | — | WO | disclosed |
| EP-0834074-B1 | DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS | UNIV CALIFORNIA (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0834074-A1 | DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5661035-A | Voltage sensing by fluorescence resonance energy transfer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0780443-A2 | Pyrrolo(2,1-a)isoquinoline dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996041166-A2 | DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283617-A1 | Biocompatible N, N-Disubstituted Sulfonamide-Containing Fluorescent Dye Labels | DNPEP, FUT5, NES | GAA 1364/4885CACNA1B 3786/4885GRIN2D 2955/4885 |
| US-20210346518-A1 | CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER | TYR, LGALS3, ABL1 | GAA 1866/4885CACNA1B 4055/4885GRIN2D 4730/4885 |
| US-20240299589-A1 | DIAGNOSING AND TREATING CANCER | CHKA, CHKB, CILK1 | GAA 1163/4885CACNA1B 3108/4885GRIN2D 4060/4885 |
| US-12527880-B2 | Cyanine-based telodendrimers and uses for treating cancer | TUBB1, CA13, YWHAZ | GAA 1911/4885CACNA1B 3297/4885GRIN2D 3227/4885 |
| US-11813338-B2 | Diagnosing and treating cancer | CHKA, CHKB, CILK1 | GAA 1163/4885CACNA1B 3108/4885GRIN2D 4060/4885 |
| US-10442930-B2 | Biocompatible N, N-disubstituted sulfonamide-containing fluorescent dye labels | DNPEP, FUT5, NES | GAA 1364/4885CACNA1B 3786/4885GRIN2D 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.